PMID- 34685403
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211026
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 11
IP  - 10
DP  - 2021 Sep 30
TI  - Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at 
      Different Doses on the Course of COVID-19-Associated Coagulopathy.
LID - 10.3390/life11101032 [doi]
LID - 1032
AB  - BACKGROUND: COVID-19-associated coagulopathy (CAC) exacerbates the course of 
      coronavirus infection and contributes to increased mortality. Current 
      recommendations for CAC treatment include the use of low-molecular weight 
      heparins (LMWH) at prophylactic or therapeutic doses, as well as the use of 
      unfractionated heparin (UFH). METHODS: A randomised, controlled trial enrolled 
      126 patients hospitalised in the intensive care unit with severe COVID-19 
      complicated by CAC. The effects of LMWH at preventive and therapeutic doses and 
      UFH at therapeutic doses on mortality and intubation rates were compared. 
      RESULTS: The number of intubations and deaths showed no significant difference 
      depending on the anticoagulant therapy used. However, multivariate logistic 
      regression models revealed an increased risk of intubation (p = 0.026, odds ratio 
      (OR) = 3.33, 95% confidence interval (CI) 1.15-9.59), and an increased risk of 
      death (p = 0.046, OR = 3.01, 95% CI 1.02-8.90), for patients treated with LMWH at 
      a prophylactic dose but not at a therapeutic dose as compared to patients treated 
      with UFH when controlling for other risk factors. CONCLUSIONS: The use of 
      unfractionated heparin in the treatment of COVID-19-associated coagulopathy seems 
      to be more effective at reducing the risk of intubation and death than enoxaparin 
      at prophylactic doses.
FAU - Oliynyk, Oleksandr
AU  - Oliynyk O
AUID- ORCID: 0000-0003-2886-7741
AD  - Department of Anaesthesiology and Intensive Care, Bogomolets National Medical 
      University, 01601 Kyiv, Ukraine.
AD  - Department of Emergency Medicine, Pope John II State School of Higher Education 
      in Biala Podlaska, 21-500 Biala Podlaska, Poland.
FAU - Barg, Wojciech
AU  - Barg W
AUID- ORCID: 0000-0001-9612-6684
AD  - Department of Internal Medicine, Pneumonology and Allergology, Wroclaw Medical 
      University, 50-367 Wroclaw, Poland.
FAU - Slifirczyk, Anna
AU  - Slifirczyk A
AD  - Department of Emergency Medicine, Pope John II State School of Higher Education 
      in Biala Podlaska, 21-500 Biala Podlaska, Poland.
FAU - Oliynyk, Yanina
AU  - Oliynyk Y
AD  - Department of Immunology and Allergology, Bogomolets National Medical University, 
      01601 Kyiv, Ukraine.
FAU - Dubrov, Serhij
AU  - Dubrov S
AD  - Department of Anaesthesiology and Intensive Care, Bogomolets National Medical 
      University, 01601 Kyiv, Ukraine.
FAU - Gurianov, Vitaliy
AU  - Gurianov V
AD  - Department of Medical Statistics, Bogomolets National Medical University, 01601 
      Kyiv, Ukraine.
FAU - Rorat, Marta
AU  - Rorat M
AUID- ORCID: 0000-0002-5318-4945
AD  - Department of Forensic Medicine, Wroclaw Medical University, 50-367 Wroclaw, 
      Poland.
LA  - eng
GR  - SUB.A120.21.030/Ministerstwo Edukacji i Nauki/
PT  - Journal Article
DEP - 20210930
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC8537389
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - anticoagulant therapy
OT  - blood coagulation
OT  - respiratory failure
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/24 06:00
MHDA- 2021/10/24 06:01
PMCR- 2021/09/30
CRDT- 2021/10/23 01:21
PHST- 2021/08/22 00:00 [received]
PHST- 2021/09/25 00:00 [revised]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/10/23 01:21 [entrez]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2021/10/24 06:01 [medline]
PHST- 2021/09/30 00:00 [pmc-release]
AID - life11101032 [pii]
AID - life-11-01032 [pii]
AID - 10.3390/life11101032 [doi]
PST - epublish
SO  - Life (Basel). 2021 Sep 30;11(10):1032. doi: 10.3390/life11101032.